# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-145511
Filing Date
2018-05-01
Accepted
2018-05-01 10:36:03
Documents
3
Effectiveness Date
2018-05-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | d578139ddefa14a.htm | DEFA14A | 12202
2 | GRAPHIC | g578139g45c23.jpg | GRAPHIC | 181951
3 | GRAPHIC | g578139g61x62.jpg | GRAPHIC | 390858
| Complete submission text file | 0001193125-18-145511.txt |  | 802828

Mailing Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017
Business Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017 (813) 864-4523
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33958 | Film No.: 18793712
SIC: 2834 Pharmaceutical Preparations